Rocket Pharmaceuticals, Inc.
General ticker "RCKT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $657.1M (TTM average)
Rocket Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -14.2%.
Estimated limits based on current volatility of 3.4%: low 3.20$, high 3.42$
Factors to consider:
- Total employees count: 299 (+11.6%) as of 2024
- Top business risk factors: Regulatory and compliance, Manufacturing risks, Labor/talent shortage/retention, Expansion risks, Geopolitical risks
- Current price 35.3% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.29$, 15.03$]
- 2025-12-31 to 2026-12-31 estimated range: [4.05$, 11.27$]
Financial Metrics affecting the RCKT estimates:
- Negative: with PPE of -4.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -18.76 <= 0.33
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0.17 <= 0.79
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
Short-term RCKT quotes
Long-term RCKT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $224.34MM | $259.66MM | $273.20MM |
| Operating Income | $-224.34MM | $-259.66MM | $-273.20MM |
| Non-Operating Income | $2.48MM | $14.06MM | $14.46MM |
| Interest Expense | $1.91MM | $1.88MM | $1.89MM |
| R&D Expense | $165.57MM | $186.34MM | $171.24MM |
| Income(Loss) | $-221.86MM | $-245.59MM | $-258.75MM |
| Profit(Loss)* | $-221.86MM | $-245.59MM | $-258.75MM |
| Stockholders Equity | $489.69MM | $492.57MM | $463.23MM |
| Assets | $551.81MM | $566.34MM | $527.70MM |
| Operating Cash Flow | $-178.14MM | $-194.92MM | $-209.72MM |
| Capital expenditure | $8.62MM | $16.47MM | $5.86MM |
| Investing Cash Flow | $-69.33MM | $-98.07MM | $131.71MM |
| Financing Cash Flow | $155.29MM | $208.40MM | $185.74MM |
| Earnings Per Share** | $-3.26 | $-2.92 | $-2.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.